Psoriasis comorbidities: complications and benefits of immunobiological treatment

about

MiR-146a G/C rs2910164 variation in South African Indian and Caucasian patients with psoriatic arthritis.

P2860

Q55025008-CF8A9FD3-230C-4AE5-B82A-3FBCA2E9D6B9

P2860

Psoriasis comorbidities: complications and benefits of immunobiological treatment

Item

http://www.wikidata.org/entity/Q37540440

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Psoriasis comorbidities: complications and benefits of immunobiological treatment

@en

Psoriasis comorbidities: complications and benefits of immunobiological treatment.

@nl

type

Item

label

Psoriasis comorbidities: complications and benefits of immunobiological treatment

@en

Psoriasis comorbidities: complications and benefits of immunobiological treatment.

@nl

prefLabel

Psoriasis comorbidities: complications and benefits of immunobiological treatment

@en

Psoriasis comorbidities: complications and benefits of immunobiological treatment.

@nl

P1476

Psoriasis comorbidities: complications and benefits of immunobiological treatment

@en

P2093

André Vicente Esteves de Carvalho

http://www.w3.org/2001/XMLSchema#string

Cacilda da Silva Souza

http://www.w3.org/2001/XMLSchema#string

Laura de Mattos Milman

http://www.w3.org/2001/XMLSchema#string

Luana Pizarro Meneghello

http://www.w3.org/2001/XMLSchema#string

Renato Soriani Paschoal

http://www.w3.org/2001/XMLSchema#string

Ricardo Romiti

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet

The metabolic syndrome--a new worldwide definition

Increased concentrations of tumour necrosis factor in "cachectic" patients with severe chronic heart failure.

Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers.

Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies.

Psoriasis and hypertension severity: results from a case-control study.

Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis.

Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months

P304

781-789

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1590/ABD1806-4841.20165080

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P5008

ScienceSource

P577

2016-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28099601

http://www.w3.org/2001/XMLSchema#string

P921

P932

5193190

http://www.w3.org/2001/XMLSchema#string

Psoriasis comorbidities: complications and benefits of immunobiological treatment

about

P2860

P2860

Psoriasis comorbidities: complications and benefits of immunobiological treatment

description

name

type

label

prefLabel

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P433

P478

P5008

P577

P698

P921

P932

P356

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P433

P478

P5008

P577

P698

P921

P932